⌕
BridgeBio Pharma · BBIO · Nasdaq
Tenet 43 · Weak
Compare
$76.80−0.72%At closeTenet 43 · Weak
$76.80−0.56 (−0.72%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

BridgeBio Pharma (BBIO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~63.8%/yr (FY21→FY25), net margin −144.4%. Worth your attention in FY25: Share count (+32.7%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲126.3%
502.1
FY21→FY25CAGR +63.8%/yr
Net income ($M)▼35.3%
−724.9
FY21→FY25CAGR —
Free cash flow ($M)▲14.3%
−447.0
FY21→FY25CAGR —
Diluted EPS▼31.3%
−3.78
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+32.7%

144.4mn → 191.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$1.1M

+17.6% YoY in FY25 · 0.2% of revenue.

Returns vs FCF
n/m

$46.1M returned vs $−447.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)502.1Revenue−21.0COGS481.1Gross profit−452.0R&D−531.2SG&A−523.4Op income−201.5Tax & other−724.9Net income

-144¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 95.5% → 95.8%. Net margin -144.4% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
945,540.0502,076.0221,902.09,303.077,648.069,716.0▲126.3%+63.8%
Cost of revenue
53,542.020,962.03,878.02,446.03,434.03,114.0▲440.5%+61.1%
Gross profit
891,998.0481,114.0218,024.06,857.074,214.066,602.0▲120.7%+63.9%
Research & development
536,007.0451,953.0506,461.0455,711.0399,462.0451,024.0▼10.8%+0.1%
Selling, general & admin
709,096.0531,225.0288,931.0150,590.0143,189.0192,210.0▲83.9%+28.9%
Total operating expenses
1,256,234.01,004,525.0810,997.0614,227.0586,416.0643,234.0▲23.9%+11.8%
Operating incomefeeds ROC rank
−364,236.0−523,411.0−592,973.0−607,370.0−512,202.0−576,632.0▲11.7%—
Other income, net
−212,232.0−209,092.050,779.0−45,881.027,550.0−9,822.0——
Pretax income
−576,468.0−732,503.0−542,194.0−653,251.0−484,652.0−586,454.0▼35.1%—
Income tax
—435.01,153.00.00.0—▼62.3%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−565,832.0−724,931.0−535,762.0−643,202.0−481,183.0−586,454.0▼35.3%—
Per share
Diluted EPSbuyback-sensitive
−3.04−3.78−2.88−3.95−3.26−3.90▼31.3%—
Diluted shares (mn)
196.03191.53186.08162.79147.47144.36▲2.9%+7.3%
Margins
Gross margin92nd pct in Healthcare
94.3%95.8%98.3%73.7%95.6%95.5%▼2.4pp+0.3pp
Operating margin
−38.5%−104.2%−267.2%−6528.8%−659.6%−827.1%▲163.0pp+722.9pp
Net margin13th pct in Healthcare
−59.8%−144.4%−241.4%−6913.9%−619.7%−841.2%▲97.1pp+696.8pp
† TTM = trailing four quarters through 2026-09-30.
FY17 – FY20 · 4 more years
Unlock the full history →
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was BridgeBio Pharma's revenue last fiscal year?

BridgeBio Pharma reported revenue of $502.1M in fiscal 2025, up 126.3% from fiscal 2024.

What was BridgeBio Pharma's net income?

BridgeBio Pharma reported net income of −$724.9M in fiscal 2025, a net margin of −144.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.